title: Carcinoma in situ of the glottic larynx: the role of radiotherapy.
abstract: OBJECTIVE
  To examine the University of Florida experience with radiotherapy of carcinoma in situ of the true vocal cord and compare our results with those reported in other series using various treatment modalities.
  
  
  METHODS
  Nineteen patients with carcinoma in situ of the true vocal cord were treated with curative intent with radiation therapy at the University of Florida between October 1964 and September 1990. All patients had a minimum 2-year follow-up. Before the radiotherapy, four patients had undergone a biopsy only, 11 patients had undergone one stripping procedure, and four patients had undergone 2 to 5 strippings. Radiation doses were between 5625 cGy and 6300 cGY (median, 5625 cGy).
  
  
  RESULTS
  The 5-year rates of local control, ultimate local control, and local control with voice preservation were 93%, 100%, and 93%, respectively. A literature review revealed that local control rates after primary treatment with radiotherapy, laser resection, and vocal cord stripping were 84%, 68%, and 66%, respectively.
  
  
  CONCLUSIONS
  Primary treatment with radiotherapy should be strongly considered for patients with carcinoma in situ of the true-vocal cord who have a recurrence after vocal cord stripping or who cannot have close follow-up after treatment.
authors.affiliation: Department of Radiation Oncology, University of Florida Health Science Center, Gainesville 32610-0385.
authors.forename: D A
authors.initials: DA
authors.lastname: Fein
authors.forename: W M
authors.initials: WM
authors.lastname: Mendenhall
authors.forename: J T
authors.initials: JT
authors.lastname: Parsons
authors.forename: S P
authors.initials: SP
authors.lastname: Stringer
authors.forename: N J
authors.initials: NJ
authors.lastname: Cassisi
authors.forename: R R
authors.initials: RR
authors.lastname: Million
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000532:radiotherapy*; D005260:Female; D005931:Glottis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary; D011879:Radiotherapy Dosage